CN¥298.80
1.90% yesterday
Shanghai, Nov 14, 08:00 am CET
ISIN
CH1391448177
Symbol
688235

BeOne Medicines Stock price

CN¥298.80
+25.09 9.17% 1M
+71.63 31.53% 6M
+137.78 85.57% YTD
+129.98 76.99% 1Y
+160.40 115.90% 3Y
+137.82 85.61% 5Y
+137.82 85.61% 10Y
+137.82 85.61% 20Y
Shanghai, Closing price Fri, Nov 14 2025
-5.79 1.90%
ISIN
CH1391448177
Symbol
688235
Industry

Key metrics

Basic
Market capitalization
CN¥289.2b
Enterprise Value
CN¥276.8b
Net debt
positive
Cash
CN¥19.7b
Shares outstanding
1.4b
Valuation (TTM | estimate)
P/E
negative | 292.8
P/S
8.8 | 7.7
EV/Sales
8.5 | 7.4
EV/FCF
205.9
P/B
10.8
Financial Health
Equity Ratio
56.4%
Return on Equity
-20.6%
ROCE
-2.4%
ROIC
-9.4%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
CN¥32.7b | CN¥37.6b
EBITDA
- | CN¥2.9b
EBIT
CN¥-709.3m | CN¥1.5b
Net Income
CN¥-1.7b | CN¥1.5b
Free Cash Flow
CN¥1.3b
Growth (TTM | estimate)
Revenue
47.7% | 38.3%
EBITDA
- | 179.3%
EBIT
89.5% | 134.2%
Net Income
62.3% | 129.8%
Free Cash Flow
113.3%
Margin (TTM | estimate)
Gross
85.4%
EBITDA
- | 7.7%
EBIT
-2.2%
Net
-5.0% | 4.0%
Free Cash Flow
4.1%
More
EPS
CN¥-1.1
FCF per Share
CN¥0.9
Short interest
-
Employees
11k
Rev per Employee
CN¥2.5m
Show more

Is BeOne Medicines a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

BeOne Medicines Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a BeOne Medicines forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a BeOne Medicines forecast:

Buy
93%
Hold
7%

Financial data from BeOne Medicines

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
32,736 32,736
48% 48%
100%
- Direct Costs 4,788 4,788
37% 37%
15%
27,948 27,948
50% 50%
85%
- Selling and Administrative Expenses 14,022 14,022
18% 18%
43%
- Research and Development Expense 14,789 14,789
9% 9%
45%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -709 -709
89% 89%
-2%
Net Profit -1,651 -1,651
62% 62%
-5%

In millions CNY.

Don't miss a Thing! We will send you all news about BeOne Medicines directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Head office Cayman Islands
Employees 11,000
Website

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today